But though an -itis can sound intense, there’s still no reason to be alarmed (or, again, to rub your eyes). To put your minds ...

Tarsus Pharmaceuticals (NASDAQ:TARS) reported fourth-quarter and full-year 2025 results highlighting rapid growth for XDEMVY, ...

OMAHA, NE - January 22, 2026 - PRESSADVANTAGE - Modern Vision Solutions has announced the publication of a new article, ...

Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year ...

Background Ocular chronic graft versus host disease (oGVHD) seriously affects ocular surface, which often results in corneal ...

Founder, President, CEO & Chairman, highlighted, “2025 was a breakout year for Tarsus and for XDEMVY. The first and only FDA-approved therapeutic for Demodex blepharitis... we delivered more than $450 ...

When Kate Lister's red eyes started bothering her she she made an appointment with an optician, who diagnosed a corneal ulcer: a sore on the clear corneal dome on the front of the eye ...

Using or reusing kajal, stick eyeliners and other eye makeup can increase the risk of bacterial contamination, irritation and infections such as conjunctivitis.

IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: TD ...

In sunny conditions, put your sunglasses on, whatever the time of year. “Just as we lather our skin with SPF, we need UV eye protection as well,” says Radia. “When you are looking to buy a trendy pair ...

Glaukos Corporation released an investor presentation in March 2026 outlining its strategy to transform glaucoma and keratoconus care through interventional, dropless therapies and to build durable ...

Before we begin, I encourage everyone to visit the Investor section of the Tarsus website to view the earnings release and re ...